about
A Polycomb-mir200 loop regulates clinical outcome in bladder cancer.Everolimus safety and efficacy for renal angiomyolipomas associated with tuberous sclerosis complex: a Spanish expanded access trial.UroMark-a urinary biomarker assay for the detection of bladder cancer.Early treatment of penile fractures: our experience.Renal biopsy with 16G needle: a safety study.Opposing roles of PIK3CA gene alterations to EZH2 signaling in non-muscle invasive bladder cancer.Adjuvant intravesical treatment for nonmuscle invasive bladder cancer: The importance of the strain and maintenance.Analysis of the Polycomb-related lncRNAs HOTAIR and ANRIL in bladder cancer.In vivo disruption of an Rb-E2F-Ezh2 signaling loop causes bladder cancer.Role of immunosuppressive treatments based on mycophenolate mofetil in posttransplantation renal surgical complications.Can partial nephrectomy preserve renal function and modify survival in comparison with radical nephrectomy?Lessons learned from the comparative study between renal mass biopsy and the analysis of the surgical specimen.PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.Urothelial cancer proteomics provides both prognostic and functional information.Safety and efficacy of various strains of bacille Calmette-Guérin in the treatment of bladder tumours in standard clinical practice.BMP4 Induces M2 Macrophage Polarization and Favors Tumor Progression in Bladder Cancer.Uncontrolled non-heartbeating donors (types i-ii) with normothermic recirculation vs. heartbeating donors: evaluation of functional results and survival.[Training program in endourological surgery. Future perspectives.][The role of chemotherapy in the treatment of hormone sensitive metastatic prostate cancer.]CDK4/6 Inhibitor as a Novel Therapeutic Approach for Advanced Bladder Cancer Independently of RB1 Status[Spanish cultural adaptation and psychometrical validation of the Treatment Benefit Scale (TBS) in the symptomatic treatment of overactive bladder]Predicting self-perceived antimuscarinic therapy effectiveness on overactive bladder symptoms using the Overactive Bladder 8-Question Awareness ToolRecurrent Aortitis Associated With IgG4-Related DiseaseRecommendations for the management of renal involvement in the tuberous sclerosis complexInhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regressionGene Expression Analyses in Non Muscle Invasive Bladder Cancer Reveals a Role for Alternative Splicing and Tp53 Status
P50
Q36561739-5B4AA200-1B9F-4C72-AA38-557EDCE42D91Q37286103-8B9620E9-CA63-4B4C-A421-4CE149AA756BQ37615895-608A72F7-700C-4AAD-9DD2-F7695C65A6DEQ38042803-4230146F-E778-408A-A54C-693202AC6B2CQ38188638-4FBE6ECA-122F-4675-BAF2-F5C88325918EQ39035829-F094EED8-1204-4463-8878-7EEE9D6109FAQ40059096-2ABF546B-C9B2-4F39-80E4-463BF5701DBEQ40442588-F48C3B8B-34F8-4444-A543-AA9D6BB4659DQ42550010-882F2F17-A9B2-4B37-A9D6-0B8AB6F469D3Q43963033-012495B6-4A32-4F0C-AE0F-1C7C1ED9A9B9Q44264593-FB8E6001-6618-4F12-8643-42D28D294F7AQ44545034-9F646E6A-B750-4433-A092-0943C3EB10F5Q44581657-CCEB866C-1E37-4FBA-B6B4-043427F245FAQ47156880-E9E213B0-E039-496D-8F91-72BF4945F555Q47218216-C1E6A094-A233-468E-9B45-6331A2CA6C37Q47687266-D32EE9C3-69EA-470A-84AB-31ADB4CB075FQ48292305-B0B7316D-8D65-4DA3-953E-2EB2550E9DB9Q50038370-0F98083E-13F4-4F31-AB77-3F80B35F21AAQ52596787-09ADF704-02B5-42C3-AA78-8E3E223F46A6Q63884106-0EC44D1B-5648-4D3C-8069-CAE9BD385376Q83275539-46DD07D0-57B3-4941-BD4B-FD66836D5640Q85318905-85D78E32-51EF-4C72-93A5-CEFEF2FE5588Q87360171-14648AE3-A620-45EA-A548-33F9ABBD6008Q91271014-F8013519-408F-4695-B913-A4A5E0A778DEQ91595589-5A51834C-58D4-4E58-946E-E9452AACDCBEQ91968395-88B7DDF0-1936-4E2C-8E3C-12AF86AC2A45
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Felipe Villacampa
@ast
Felipe Villacampa
@en
Felipe Villacampa
@es
Felipe Villacampa
@nl
type
label
Felipe Villacampa
@ast
Felipe Villacampa
@en
Felipe Villacampa
@es
Felipe Villacampa
@nl
prefLabel
Felipe Villacampa
@ast
Felipe Villacampa
@en
Felipe Villacampa
@es
Felipe Villacampa
@nl
P106
P1153
15748766900
P21
P31
P496
0000-0001-6779-6945